Skip to main content
Equibles
NAMS logo

NAMS · NewAmsterdam Pharma Co N.V. · Webcasts, Transcripts & Audio

Track NAMS — free

Use NAMS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NAMS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$21.90 +0.40 (+1.86%)
Rebalance outlook locked
Market Cap
$2.57B
Shares
119.54M
Volume · Oct 20 1.08M Avg daily vol (3M) 1.4M

NewAmsterdam Pharma Co N.V. Webcasts

Earnings calls, investor updates, investor days and conferences for NewAmsterdam Pharma Co N.V. (NAMS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-05
NewAmsterdam Pharma Co N.V. (NAMS) Q2 2026 Earnings Call
Revenue
$3.70M
▼ 80.7% YoY
Diluted EPS
$-0.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
NewAmsterdam Pharma Co N.V. (NAMS) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
NewAmsterdam Pharma Co N.V. (NAMS) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-13
NewAmsterdam Pharma Co N.V. (NAMS) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
NewAmsterdam Pharma Co N.V. (NAMS) Q1 2026 Earnings Call
Revenue
$3.04M
▲ 2.1% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-11
NewAmsterdam Pharma Co N.V. (NAMS) Q4 2025 Earnings Call
Revenue
$32,000*
▼ 99.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
NewAmsterdam Pharma Co N.V. (NAMS) Q3 2025 Earnings Call Transcript
Revenue
$348,000
▼ 98.8% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
NewAmsterdam Pharma Co N.V. (NAMS) Q2 2025 Earnings Call Transcript
Confident tone PREVAIL Trial Design and Interim Analysis Broadway Trial as Predictor Alzheimer's / Phase 2B Program
Revenue
$19.14M
▲ 740.1% YoY
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
NewAmsterdam Pharma Co N.V. (NAMS) Q1 2025 Earnings Call
Revenue
$2.98M
▲ 112.6% YoY
Diluted EPS
$-0.34
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
NewAmsterdam Pharma Co N.V. (NAMS) Q4 2024 Earnings Call
Revenue
$12.77M*
▲ 1490.5% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
NewAmsterdam Pharma Co N.V. (NAMS) Q3 2024 Earnings Call
Revenue
$29.11M
▲ 889.8% YoY
Diluted EPS
$-0.18
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
NewAmsterdam Pharma Co N.V. (NAMS) Q2 2024 Earnings Call
Revenue
$2.28M
▲ 32.7% YoY
Diluted EPS
$-0.41
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
NewAmsterdam Pharma Co N.V. (NAMS) Q1 2024 Earnings Call
Revenue
$1.40M
▼ 83.8% YoY
Diluted EPS
$-1.06
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
NewAmsterdam Pharma Co N.V. (NAMS) Q4 2023 Earnings Call
Revenue
$803,000*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–14 of 14 webcasts
Key facts CIK 1936258 CUSIP N62509109 13F (30d) 8 filings 8 filers Visit website Investor relations